Topologically non-trivial metal-organic assemblies inhibit β2-microglobulin amyloidogenesis
Source abstract
Abstract
Inhibiting amyloid aggregation through high-turnover dynamic interactions could be an efficient strategy that is already used by small heat-shock proteins in different biological contexts. We report the interactions of three topologically non-trivial, zinc-templated metal-organic assemblies, a [2]catenane, a trefoil knot (TK), and Borromean rings, with two β2-microglobulin (β2m) variants responsible for amyloidotic pathologies. Fast exchange and similar patterns of preferred contact surface are observed by NMR, consistent with molecular dynamics simulations. In vitro fibrillation is inhibited by each complex, whereas the zinc-free TK induces protein aggregation and does not inhibit fibrillogenesis. The metal coordination imposes structural rigidity that determines the contact area on the β2m surface depending on the complex dimensions, ensuring in vitro prevention of fibrillogenesis. Administration of TK, the best protein-contacting species, to a disease-model organism, namely a Caenorhabditis elegans mutant expressing the D76N β2m variant, confirms the bioactivity potential of the knot topology and suggests new developments.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Enzyme Structure and Function · Protein Structure and Dynamics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (71)
Show source-provided references
1. The amyloid state and its association with protein misfolding diseases10.1038/nrm3810 ↗
2. Natural supramolecular protein assemblies10.1039/C5CS00157A ↗
3. Protein misfolding, functional amyloid, and human disease10.1146/annurev.biochem.75.101304.123901 ↗
4. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases10.1016/j.bbagen.2013.06.029 ↗
5. Mechanisms for the inhibition of amyloid aggregation by small ligands10.1042/BSR20160101 ↗
6. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade10.1073/pnas.1121005109 ↗
7. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis10.1126/science.1079469 ↗
8. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease10.1097/WNF.0b013e3181cb577a ↗
9. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease10.1016/j.jmb.2011.11.047 ↗
10. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme10.1038/nature01870 ↗
11. A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo10.1038/srep46711 ↗
12. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis10.15252/emmm.201505357 ↗
13. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function?10.1080/15216540310001640498 ↗
14. AlphaB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid β-peptide and β2-microglobulin10.1042/BJ20050339 ↗
15. Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers10.1074/jbc.M112.448639 ↗
16. Biological and chemical approaches to diseases of proteostasis deficiency10.1146/annurev.biochem.052308.114844 ↗
17. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils10.1074/jbc.M110.178376 ↗
18. Using pharmacological chaperones to restore proteostasis10.1016/j.phrs.2014.04.002 ↗
19. Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases10.1021/acschembio.6b00195 ↗
20. Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis10.3109/13506129.2013.803463 ↗
21. A new face for old antibiotics: tetracyclines in treatment of amyloidoses10.1021/jm400161p ↗
22. Gold nanoparticles as amyloid-like fibrillogenesis inhibitors10.1016/j.colsurfb.2013.08.029 ↗
23. Influence of gold nanoparticle surface chemistry and diameter upon Alzheimer’s disease amyloid-β protein aggregation10.1186/s13036-017-0047-6 ↗
24. Citrate-stabilized gold nanoparticles hinder fibrillogenesis of a pathological variant of β2-microglobulin10.1039/C6NR09362K ↗
25. The effect of nanoparticles on amyloid aggregation depends on the protein stability and intrinsic aggregation rate10.1021/la203078w ↗
26. Cyclotides as drug design scaffolds10.1016/j.cbpa.2017.01.018 ↗
27. Cyclotides: disulfide-rich peptide toxins in plants10.1016/j.toxicon.2019.10.244 ↗
28. Engineering knottins as novel binding agents10.1016/B978-0-12-396962-0.00009-4 ↗
29. Synthetic Cystine-Knot Miniproteins - Valuable Scaffolds for Polypeptide Engineering10.1007/978-3-319-32805-8_7 ↗
30. Simultaneous self-assembly of a [2]catenane, a trefoil knot, and a Solomon link from a simple pair of ligands10.1002/anie.201302425 ↗
31. [C-H···anion] interactions mediate the templation and anion binding properties of topologically non-trivial metal-organic structures in aqueous solutions10.1039/C5SC04246A ↗
32. Molecular borromean rings10.1126/science.1096914 ↗
33. A new form of amyloid protein associated with chronic hemodialysis was identified as β 2-microglobulin10.1016/0006-291X(85)91948-5 ↗
34. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin10.1056/NEJMoa1201356 ↗
35. Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin10.1074/jbc.M113.498857 ↗
36. Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy10.1016/0009-2614(80)80041-8 ↗
37. Altered flexibility in the substrate-binding site of related native and engineered high-alkaline Bacillus subtilisins10.1006/jmbi.1999.3034 ↗
38. Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy10.1021/ja00034a071 ↗
39. The solution structure of human β2-microglobulin reveals the prodromes of its amyloid transition10.1110/ps.29002 ↗
40. Structure of the human class I histocompatibility antigen, HLA-A210.1038/329506a0 ↗
41. Removal of the N-terminal hexapeptide from human β2-microglobulin facilitates protein aggregation and fibril formation10.1110/ps.9.5.831 ↗
42. Chloride-sensitive fluorescent indicators10.1006/abio.2001.5103 ↗
43. Folding and fibrillogenesis: clues from β2-microglobulin10.1016/j.jmb.2010.06.016 ↗
44. Caenorhabditis elegans as a model in developmental toxicology10.1007/978-1-61779-867-2_3 ↗
45. Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer10.1073/pnas.0601931103 ↗
46. C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype10.1371/journal.pone.0052314 ↗
47. Modeling neurodegenerative diseases in Caenorhabditis elegans10.1016/j.expneurol.2013.09.024 ↗
48. Utility of an improved model of amyloid-beta (A β₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease10.1186/1750-1326-7-57 ↗
49. Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans10.1073/pnas.1801117115 ↗
50. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan10.1038/nature09873 ↗
51. C. elegans expressing D76N β2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis10.1038/s41598-019-56498-5 ↗
52. An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes10.1016/j.ijpddr.2017.11.004 ↗
53. Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro10.3109/13506129709003833 ↗
54. Post-synthetic modifications of cadmium-based knots and links10.1039/C6CC02423H ↗
55. Pulsed-field gradients: theory and practice10.1016/S0076-6879(94)39006-1 ↗
56. Convection Compensation in Gradient Enhanced Nuclear Magnetic Resonance Spectroscopy10.1006/jmre.1998.1400 ↗
57. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions10.1007/BF02192855 ↗
58. Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients10.1006/jmra.1995.1047 ↗
59. The importance of not saturating water in protein NMR. Application to sensitivity enhancement and NOE measurements10.1021/ja00079a052 ↗
60. Bluues: a program for the analysis of the electrostatic properties of proteins based on generalized Born radii10.1186/1471-2105-13-S4-S18 ↗
61. Bluues server: electrostatic properties of wild-type and mutated protein structures10.1093/bioinformatics/bts343 ↗
62. GROMACS: a message-passing parallel molecular dynamics implementation10.1016/0010-4655(95)00042-E ↗
63. NAMD2: Greater Scalability for Parallel Molecular Dynamics10.1006/jcph.1999.6201 ↗
64. Improved side-chain torsion potentials for the Amber ff99SB protein force field10.1002/prot.22711 ↗
65. Amino acid empirical contact energy definitions for fold recognition in the space of contact maps10.1186/1471-2105-4-8 ↗
66. A new model for calculating atomic charges in molecules10.1016/S0040-4039(01)94977-9 ↗
67. Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges10.1016/0040-4020(80)80168-2 ↗
68. Generalized born models of macromolecular solvation effects10.1146/annurev.physchem.51.1.129 ↗
69. Exploring protein native states and large-scale conformational changes with a modified generalized born model10.1002/prot.20033 ↗
70. Application of a pairwise generalized Born model to proteins and nucleic acids: inclusion of salt effects10.1007/s002140050460 ↗
71. ThT 101: a primer on the use of thioflavin T to investigate amyloid formation10.1080/13506129.2017.1304905 ↗